<DOC>
	<DOCNO>NCT00376415</DOCNO>
	<brief_summary>Lessertia frutescens ( L. ) Goldblatt &amp; J.C. Manning ( syn . Sutherlandia frutescens ( L. ) R . Br . ) , infusion decoction widely use South Africa indigenous medicine , combat cancer , infection symptom associated AIDS . The aim study evaluate safety phytotherapy healthy adult .</brief_summary>
	<brief_title>A Safety Study Lessertia Frutescens Adults .</brief_title>
	<detailed_description>Objectives : Lessertia frutescens ( L. ) Goldblatt &amp; J.C. Manning ( syn . Sutherlandia frutescens ( L. ) R . Br . ) , infusion decoction widely use South Africa indigenous medicine , combat cancer , infection symptom associated AIDS . The aim study evaluate safety phytotherapy healthy adult . Design : A randomised , double blind , placebo-controlled trial evaluate safety Lessertia frutescens healthy adult . Setting : Karl Bremer Hospital , Bellville , South Africa . Participants : 25 adult , age 18 45 year , provide informed consent . They significant disease clinically abnormal laboratory blood profile screen . They history allergic condition regular medical treatment . Intervention : 12 healthy participant randomize treatment arm receive 400mg L. frutescens leaf powder capsule twice daily ( 800mg/day ) , available product call Sutherlandia . 13 healthy participant randomize control arm , receive identical placebo capsule . The trial last 3 month . Outcome Measures : The primary endpoint frequency adverse event secondary endpoint , change physical , vital , blood biomarker index . Results : There significant difference general adverse event , cardiovascular , CNS , GIT , infection , allergy , malaise , physical , haematological , biochemical physiological parameter , treatment placebo group ( P &gt; 0.05 ) . However , subject consume L. frutescens mostly report improve appetite compare placebo group ( P &lt; 0.01 ) . Although treatment group exhibit low respiration rate ( P &lt; 0.04 ) , high platelet count ( P &lt; 0.03 ) , MCH ( P &lt; 0.01 ) , MCHC ( P &lt; 0.02 ) , total protein ( P &lt; 0.03 ) albumin level ( P &lt; 0.03 ) , placebo group , difference remain within normal physiological range , clinically relevant . The L. frutescens biomarker , Canavanine , undetectable subject plasma . Conclusion : Overall , consumption 800mg/day L. frutescens leaf powder capsule , well tolerate healthy adult .</detailed_description>
	<criteria>Healthy male females 18 45 year age : informed nature study give write informed consent ; body weight within 25 % appropriate range ; significant decrease clinically abnormal laboratory value screen ; 12 lead ECG without significant abnormality ; regular medical treatment ; able communicate effectively study personnel . Any disease condition might compromise haematopoietic , renal , endocrine , pulmonary , central nervous system , cardiovascular , immunological , dermatological , gastrointestinal body system . History allergic condition asthma , urticaria eczema . History autoimmune disorder Lupus erythematosis . History presence dyspepsia , gastric ulcer duodenal ulcer . History psychiatric disorder . Intake medication within 14 day start study . Recent history alcoholism ( &lt; 2 year ) consumption alcohol within 48 hour receive study medication . Smokers smoke 10 cigarette per day refrain smoke study period . Presence clinically significant abnormal laboratory result screen . Pregnancy use appropriate mean contraception . Use recreational drug history drug addiction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Lessertia frutescens</keyword>
	<keyword>Sutherlandia frutescens</keyword>
	<keyword>Phase 1 clinical trial</keyword>
	<keyword>Human safety study</keyword>
</DOC>